ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Mechanism-Driven Nanoformulations for Cognitive Impairment Induced by Intermittent Hypoxia and Periodontitis.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Cognitive impairment is a growing global health challenge, yet its multifactorial drivers remain incompletely understood. Intermittent hypoxia (IH) and periodontitis are identified as significant independent risk factors that frequently co-occur. This study investigates the mechanisms through which these conditions accelerate cognitive decline. Here, utilizing a comorbid mouse model, we demonstrate that outer membrane vesicles (OMVs) derived from Porphyromonas gingivalis exacerbate IH-induced mitochondrial oxidative stress and neuroinflammation, leading to neuronal damage and mitochondrial dysfunction in the hippocampus. Specifically, this process is driven by the activation of the HIF-1α/HMGB1/NLRP3 signaling axis. To target this pathology, an asymmetric RVG-Au&mSiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.